{
    "clinical_study": {
        "@rank": "156254", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental", 
                "description": "SQ DENVax using needle/syringe"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "IM DENVax using needle/syringe"
            }, 
            {
                "arm_group_label": "Group 3", 
                "arm_group_type": "Experimental", 
                "description": "IM DENVax using needle/syringe"
            }, 
            {
                "arm_group_label": "Group 4", 
                "arm_group_type": "Experimental", 
                "description": "SQ DENVax using needless injector"
            }, 
            {
                "arm_group_label": "Group 5", 
                "arm_group_type": "Experimental", 
                "description": "IM DENVax using needless injector"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the Safety and Immunogenicity of DENVax vaccination via SC or IM\n      administration with needle/syringe or needle-less injector"
        }, 
        "brief_title": "Impact of SQ vs IM Administration of DENVax on Safety and Immunogenicity", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  In good health as determined by medical history, physical examination and laboratory\n             tests\n\n          -  Negative for HIV, Hepatitis B & C\n\n        Exclusion Criteria:\n\n          -  History of Dengue fever, Japanese encephalitis, West Nile or Yellow Fever disease\n\n          -  Seropositivity to dengue or West Nile virus\n\n          -  Extensive scarring or tattoo (> 50%) on arms, shoulders, neck face and head\n\n          -  History of significant dermatologic disease in the last 6 months\n\n          -  Receipt or planned receipt of any vaccine in the 4 weeks preceding or following the\n             vaccinations\n\n          -  Use of systemic corticosteroids therapy within the previous 6 months (at a dose of\n             0.5 mg/kg/day).  Topical prednisone is not permitted if currently in use or used\n             within the last month.\n\n          -  Planned donation of blood during the period of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01728792", 
            "org_study_id": "INV-DEN-105"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group 1", 
                "Group 2", 
                "Group 3", 
                "Group 4", 
                "Group 5"
            ], 
            "description": "DENVax is a live attenuated Dengue vaccine", 
            "intervention_name": "DENVax", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Normal", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Syracuse", 
                    "country": "United States", 
                    "state": "New York"
                }, 
                "name": "Upstate Medical University"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "Impact of Subcutaneous Versus Intramuscular Administration of Inviragens Live Attenuated Dengue Vaccine on Safety and Immunogenicity", 
        "overall_official": {
            "affiliation": "Upstate Medical University", 
            "last_name": "Mark Polhemus, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Adverse events including injection site reactions.", 
            "safety_issue": "Yes", 
            "time_frame": "Each study visit from baseline to day 120."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01728792"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Viremia and neutralizing antibodies will measured.", 
            "safety_issue": "Yes", 
            "time_frame": "Days 30 and 120"
        }, 
        "source": "Inviragen Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Walter Reed Army Institute of Research (WRAIR)", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "Inviragen Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}